Trials / Recruiting
RecruitingNCT06104839
Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (estimated)
- Sponsor
- NEXTGEN Bioscience · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NXC736 | oral administration |
| DRUG | Placebo | oral administration |
Timeline
- Start date
- 2024-09-01
- Primary completion
- 2026-10-31
- Completion
- 2027-01-31
- First posted
- 2023-10-27
- Last updated
- 2026-04-13
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06104839. Inclusion in this directory is not an endorsement.